Authors
Sumeyya Deniz Aybek, Mucahit Secme, Gonca Gulbay
Published in
Molecular biology reports. Volume 53. Issue 1. Sep 23, 2026. Epub Sep 23, 2026.
Abstract
Uterine leiomyosarcoma (uLMS) is the most common subtype of uterine sarcomas characterized by high recurrence, metastasis rates, and limited responsiveness to conventional therapies. Zerumbone has been proven that have chemotherapeutic effects on cancer by modulating many molecular targets. The present study aimed to evaluate, for the first time, the antiproliferative potential of zerumbone against SK-UT-1 human uterine leiomyosarcoma cells.
Cell viability was assessed by CCK-8 assay. To evaluate the effect of zerumbone on apoptosis and cell cycle progression in SK-UT-1 cells, Annexin V and PI staining apoptosis assay and the PI staining assay were performed, respectively. To determine the cell cycle regulation and apoptosis-related gene expression changes, total RNA was isolated from SK-UT-1 cells treated with zerumbone and untreated control cells. The cDNAs were synthesized by Reverse transcription assay, and gene expressions were analysed using qRT-PCR. Zerumbone significantly decreased the viability of SK-UT-1 cells in a dose- and time-dependent manner. Flow cytometry analysis revealed that zerumbone induced G0/G1-phase arrest, followed by apoptosis and suppressed cell proliferation in SK-UT-1 cells.
Thus, our data indicate that zerumbone may represent a promising candidate for further investigation as potential therapeutic agents for uLMS, including its possible use in combination therapy.
PMID:
42776289
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0